Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage 2020 Preview
The Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a flourish, and areas like cancer, vaccines and diabetes are poised to continue this with strong sales in 2020. However, the wider sector will need to deliver on its innovation promises next…
Report library
First-line lung cancer: can Keytruda be stopped?
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…
EvaluateMedTech World Preview 2018, Outlook to 2024
Report Highlights Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players Neurology set to be the…
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of…
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
EvaluatePharma Orphan Drug Report 2018
Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.